Tyler Rice

There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.

Researchers analyzed the efficacy of interdisciplinary multimodal integrated care in patients with chronic migraine and/or tension-type headache.

Patients with migraine who have more headache-free days experience less work productivity loss and activity impairment and lower healthcare resource use.

Botulinum toxin was found to reduce migraine frequency in adults with chronic migraine by two days per month without significant adverse events.

Lasmiditan may provide effective acute relief from migraine, with sustained improvements in freedom from pain, most bothersome symptoms, total migraine, and disability.

The use of lasmiditan for the treatment of migraine may be associated with a dose-dependent incidence of mild to moderate dizziness.

The prevalence of cluster headache may be higher in individuals with a substance use disorder than in the general population.

There may be a bidirectional relationship between fibromyalgia and migraine.

The use of metoclopramide and non-steroidal anti-inflammatory drugs during migraine attacks may be associated with insulin resistance in women with migraine.

Individuals with vs without migraine may be more likely to have comorbid dry eye disease.

Levels of migraine-related disability, physical functioning, and tenderness, but not catastrophizing, may allow to distinguish between chronic and episodic migraine in children and adolescents.

Investigators sought to establish the effect of hyperglycemia and metformin use on relevant B-vitamin biomarkers and cognitive outcomes in older adults.

The Headache-specific Locus of Control scale may represent a reliable and valid tool to assess headache-specific locus of control in individuals with migraine.